Cryptome and NTRI to Work on Brain Trauma Drugs

07-Jul-2005

Cryptome Pharmaceuticals and the National Trauma Research Institute (NTRI) at The Alfred hospital, a member of Bayside Health, signed an agreement that will accelerate Cryptome's drug discovery platform in neuroinflammation.

Using highly specialized clinical source materials from the NTRI, Cryptome will apply its proprietary Cryptomics(TM) drug discovery technology to find novel protein fragments (crypteins) which could potentially be used as drugs to prevent or limit damage from inflammatory or traumatic injury of the brain

While any drug candidates discovered will be owned by Cryptome, the agreement also gives NTRI the right to develop its own novel intellectual property from the libraries of protein fragments developed by Cryptome. With Cryptome as the commercial partner for all emerging drug candidates, both the business interests of Cryptome and the basic research interests of the NTRI will be significantly advanced.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances